N1-((S)-1-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N10-(4-((6-(1-(2-((4-methyl-3-(trifluoromethyl)phenyl)amino)-2-oxoethyl)-1H-pyrazol-4-yl)-1H-indazol-3-yl)carbamoyl)phenyl)decanediamide

ID: ALA5265863

Chembl Id: CHEMBL5265863

Max Phase: Preclinical

Molecular Formula: C59H66F3N11O7S

Molecular Weight: 1130.31

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1ccc(NC(=O)Cn2cc(-c3ccc4c(NC(=O)c5ccc(NC(=O)CCCCCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCc6ccc(-c7scnc7C)cc6)C(C)(C)C)cc5)n[nH]c4c3)cn2)cc1C(F)(F)F

Standard InChI:  InChI=1S/C59H66F3N11O7S/c1-35-14-22-43(27-46(35)59(60,61)62)67-51(77)33-72-31-41(30-65-72)40-21-25-45-47(26-40)70-71-54(45)69-55(78)39-19-23-42(24-20-39)66-49(75)12-10-8-6-7-9-11-13-50(76)68-53(58(3,4)5)57(80)73-32-44(74)28-48(73)56(79)63-29-37-15-17-38(18-16-37)52-36(2)64-34-81-52/h14-27,30-31,34,44,48,53,74H,6-13,28-29,32-33H2,1-5H3,(H,63,79)(H,66,75)(H,67,77)(H,68,76)(H2,69,70,71,78)/t44-,48+,53-/m1/s1

Standard InChI Key:  OMBFZCSGOOTQOG-WDXSTBBASA-N

Alternative Forms

  1. Parent:

    ALA5265863

    ---

Associated Targets(Human)

HGC-27 (1452 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HEK-293T (167025 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HUVEC (11049 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
GES1 (603 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KDR Tclin VHL/Vascular endothelial growth factor receptor 2 (56 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KDR Tclin Vascular endothelial growth factor receptor 2 (20924 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 1130.31Molecular Weight (Monoisotopic): 1129.4819AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Wang XR, Wang S, Mu HX, Xu KY, Wang XT, Shi JT, Cui QH, Zhang LW, Chen SW..  (2022)  Discovery of novel VEGFR-2-PROTAC degraders based on the localization of lysine residues via recruiting VHL for the treatment of gastric cancer.,  244  [PMID:36242985] [10.1016/j.ejmech.2022.114821]

Source